SERENTIL® (MESORIDAZINE BESYLATE) HAS BEEN SHOWN TO PROLONG THE QTc INTERVAL IN A DOSE RELATED MANNER, AND DRUGS WITH THIS POTENTIAL, INCLUDING SERENTIL, HAVE BEEN ASSOCIATED WITH TORSADE DE POINTES-TYPE ARRHYTHMIAS AND SUDDEN DEATH. DUE TO ITS POTENTIAL FOR SIGNIFICANT, POSSIBLY LIFE-THREATENING, PROARRHYTHMIC EFFECTS, SERENTIL SHOULD BE RESERVED FOR USE IN THE TREATMENT OF SCHIZOPHRENIC PATIENTS WHO FAIL TO SHOW AN ACCEPTABLE RESPONSE TO ADEQUATE COURSES OF TREATMENT WITH OTHER ANTIPSYCHOTIC DRUGS, EITHER BECAUSE OF INSUFFICIENT EFFECTIVENESS OR THE INABILITY TO ACHIEVE AN EFFECTIVE DOSE DUE TO INTOLERABLE ADVERSE EFFECTS FROM THOSE DRUGS. (SEE WARNINGS, CONTRAINDICATIONS, AND INDICATIONS.)
SERENTIL® (mesoridazine besylate), the besylate salt of a metabolite of thioridazine, is a phenothiazine antipsychotic. Serentil is 10-[2(1-methyl-2-piperidyl)ethyl]-2-(methyl-sulfinyl)-phenothiazine [as the besylate].
Serentil® (mesoridazine besylate) is indicated for the management of schizophrenic patients who fail to respond adequately to treatment with other antipsychotic drugs. Due to the risk of significant, potentially life-threatening, proarrhythmic effects with Serentil treatment, Serentil should be used only in patients who have failed to respond adequately to treatment with appropriate courses of other antipsychotic drugs, either because of insufficient effectiveness or the inability to achieve an effective dose due to intolerable adverse effects from those drugs. Consequently, before initiating treatment with Serentil, it is strongly recommended that a patient be given at least two trials, each with a different antipsychotic drug product at an adequate dose, and for an adequate duration (see WARNINGS and CONTRAINDICATIONS).
However, the prescriber should be aware that Serentil has not been systematically evaluated in controlled trials in treatment of refractory schizophrenic patients and its efficacy in such patients is unknown.
Media Articles Related to Serentil (Mesoridazine)
Siblings of Schizophrenia Patients at Greater Risk for Same Diagnosis: Study
Source: MedicineNet Schizophrenia Specialty [2016.09.21]
Title: Siblings of Schizophrenia Patients at Greater Risk for Same Diagnosis: Study
Category: Health News
Created: 9/21/2016 12:00:00 AM
Last Editorial Review: 9/21/2016 12:00:00 AM
Medication against schizophrenia inhibits pancreatic cancer
Source: Schizophrenia News From Medical News Today [2016.09.09]
A receptor for the dopamine neurotransmitter promotes growth and spread of pancreatic cancer - and schizophrenia drugs, which block the function of this receptor, slowed tumor growth and metastatic...
Sleep apnoea blamed for schizophrenia complications
Source: Schizophrenia News From Medical News Today [2016.08.29]
Undiagnosed sleep apnoea is being blamed for high rates of cardiovascular disease and memory loss among people with schizophrenia.
Schizophrenia: Symptoms, Types, Causes, and Treatment
Source: MedicineNet Alcohol Abuse and Alcoholism Specialty [2016.08.26]
Title: Schizophrenia: Symptoms, Types, Causes, and Treatment
Created: 9/27/2010 9:31:00 AM
Last Editorial Review: 8/26/2016 12:00:00 AM
Schizophrenia symptoms eased with aerobic exercise
Source: Schizophrenia News From Medical News Today [2016.08.12]
Around 12 weeks of aerobic exercise was found to significantly improve the cognitive functioning of individuals with schizophrenia in a new study.
Published Studies Related to Serentil (Mesoridazine)
Comparison of the effects of thioridazine and mesoridazine on the QT interval in healthy adults after single oral doses. [2007.11]
We compared the effects of single doses of thioridazine and mesoridazine on the heart rate-corrected QT (QTc) interval in healthy adult volunteers. QTc intervals and plasma concentrations of thioridazine, mesoridazine, and metabolites were measured after single oral doses of thioridazine hydrochloride 50 mg, mesoridazine besylate 50 mg, or placebo in a double-blind, crossover study...
Clinical Trials Related to Serentil (Mesoridazine)
Reducing Antipsychotic-Induced Weight Gain in Children With Metformin [Recruiting]
Recent but limited short term studies have shown that Metformin can slow down weight gain in
obese children and in children with psychotropic-induced weight gain, two distinct pediatric
populations that are at risk for obesity related co-morbid conditions. The purpose of this
study is to conduct a long term prospective pilot cohort study to investigate the use of
Metformin to prevent or decrease weight gain in two cohorts of children: 1) children with
psychotropic induced weight gain on Metformin and 2) children with BMI above the 95th
percentile on Metformin. Both study populations will be enrolled in a lifestyle weight
Page last updated: 2016-09-21